SUCRA and P scores for ranking of maintenance agents based on PFS and OS for transplant-ineligible patients
| Maintenance agent . | SUCRA . | P score . |
|---|---|---|
| PFS (all cytogenetic risk groups) | ||
| Len | 96% | 100% |
| Ixa | 50% | 50% |
| Placebo | 3% | 0% |
| PFS (all cytogenetic risk groups: sensitivity analysis by excluding HOVON trial) | ||
| Len | 92% | 100% |
| Ixa | 53% | 50% |
| Placebo | 5% | 0% |
| PFS (cytogenetic high risk) | ||
| Len | 85% | 96% |
| Ixa | 51% | 51% |
| Placebo | 14% | 3% |
| PFS (cytogenetic standard risk) | ||
| Len | 79% | 88% |
| Ixa | 63% | 61% |
| Placebo | 8% | 0% |
| OS (all cytogenetic risk groups) | ||
| Len | 62% | 61% |
| Ixa | 45% | 45% |
| Placebo | 43% | 44% |
| Maintenance agent . | SUCRA . | P score . |
|---|---|---|
| PFS (all cytogenetic risk groups) | ||
| Len | 96% | 100% |
| Ixa | 50% | 50% |
| Placebo | 3% | 0% |
| PFS (all cytogenetic risk groups: sensitivity analysis by excluding HOVON trial) | ||
| Len | 92% | 100% |
| Ixa | 53% | 50% |
| Placebo | 5% | 0% |
| PFS (cytogenetic high risk) | ||
| Len | 85% | 96% |
| Ixa | 51% | 51% |
| Placebo | 14% | 3% |
| PFS (cytogenetic standard risk) | ||
| Len | 79% | 88% |
| Ixa | 63% | 61% |
| Placebo | 8% | 0% |
| OS (all cytogenetic risk groups) | ||
| Len | 62% | 61% |
| Ixa | 45% | 45% |
| Placebo | 43% | 44% |
Abbreviations are explained in Table 1.